Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi, multiple myeloma
Sanofi breaks into first-line multiple myeloma with FDA approval for Sarclisa
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. | Since an initial FDA go-ahead in 2020,
Sanofi wins US approval for drug combination to treat multiple myeloma
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed,
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
1d
Sanofi Says FDA Approves Sarclisa for Treatment of Blood Cancer Patients
Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...
ENDPOINTS NEWS
1d
Sanofi's Sarclisa gets approved as a first-line option for some patients newly diagnosed with multiple myeloma
Despite largely exiting oncology, Sanofi continues to reap the benefit of its multiple myeloma treatment Sarclisa. The FDA on ...
devdiscourse
2h
Key Developments in Health: Novo Nordisk's Wegovy, Zevra's Breakthrough, and More
This summary highlights major health news, including EU's endorsement of Novo Nordisk's Wegovy for heart conditions in ...
18d
Sanofi: A Long-Term Cash Cow With High Dividends
Sanofi's Inhibrx acquisition strengthens its position in the global alpha-1 antitrypsin deficiency treatment market. See why ...
18d
on MSN
Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials
Sanofi SA’s (NASDAQ:SNY) data from the HERCULES phase 3 study showed that tolebrutinib met the primary endpoint of ...
devdiscourse
1d
Latest Health Developments: Key Approvals and Controversies
Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...
1d
Sanofi: A Strong Buy on Earnings Growth, Pipeline Progress, and Market Catalysts
Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...
Pharmabiz
15d
ALX Oncology doses first patients for UMBRELLA phase 1/2 study with Sanofi to evaluate evorpacept in combination with Sarclisa
South San Franciso, California Friday, September 6, 2024, 16:30 Hrs [IST] ...
18d
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback